ClinicalTrials.gg
CompletedNCT01393600Updated Aug 10, 2017Results posted

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

A Phase 2 interventional study of NBI-98854 and NBI-98854 in Tardive Dyskinesia, sponsored by Neurocrine Biosciences. Completed at 11 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-08-10.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.

Enrollment
11th of 14
37 · median 101
Started
2011
with 1 other
Phase 2
4 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
11 of 14
Neurocrine Biosciences

Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 11th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 2, and was the 2nd registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About valbenazine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing valbenazine in Tardive Dyskinesia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses (12.5 and 50 mg) of NBI-98854 administered once daily (q.d.) for the treatment of tardive dyskinesia in subjects with schizophrenia or schizoaffective disorder.

03

Conditions studied

  • Tardive Dyskinesia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a clinical diagnosis of schizophrenia or schizoaffective disorder and a clinical diagnosis of neuroleptic-induced tardive dyskinesia as defined in the , 4th edition (DSM-IV), 333.82 (see Appendix 17.1) for at least 3 months prior to screening.
  • Be receiving a stable dose of antipsychotic medication for a minimum of 30 days before study start. Subjects who are not using antipsychotic medication must have stable psychiatric status.
  • Have the doses of concurrent medications and the conditions being treated be stable for a minimum of 30 days before study start and be expected to remain stable during the study.
  • Subjects of must agree to use hormonal or two forms of nonhormonal during the study.
  • Female subjects must not be pregnant.
  • Be in good general health and expected to complete the clinical study as designed.
  • Have a (BMI) of 18 to 38 kg/m2 (both inclusive).
  • Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.
  • Have a negative urine drug screen (negative for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids) at screening and study start, except for any subject receiving a stable dose of benzodiazepine.
  • Have a negative alcohol breath test at screening and study start.

Exclusion criteria

Exclusion Criteria:

  • Have an active unstable medical condition within 1 month (30 days) prior to screening.
  • Have a history of substance dependence or substance (drug) or alcohol abuse within the 3 months before study start(nicotine and caffeine dependence are not exclusionary).
  • Have a known history of neuroleptic malignant syndrome.
  • Have a significant risk of suicidal or violent behavior.
  • Receiving any excluded concomitant medication such as reserpine, metoclopramide, stimulants, or tetrabenazine
  • Receiving medication for the treatment of tardive dyskinesia.
  • Have a positive antibody, (HIV-Ab), surface antigen (HBsAg), or virus (HCV) antibody result at screening or have a history of positive result.
  • Have received an drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study.
  • Have an allergy, , or intolerance to tetrabenazine.
  • Have had previous exposure with NBI-98854.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    NBI-98854 12.5 mg

    During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences: Sequence 1: Placebo once daily dose for Days 1-14 and 12.5 mg NBI-98854 once daily dose for Days 15-28. Sequence 2: 12.5 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28.

    Drug: NBI-98854 · Drug: Placebo

  • Experimental
    NBI-98854 50 mg

    During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences: Sequence 3: Placebo once daily dose for Days 1-14 and 50 mg NBI-98854 once daily dose for Days 15-28. Sequence 4: 50 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28.

    Drug: NBI-98854 · Drug: Placebo

Interventions

  • 12.5 mg powder in bottle once daily for 14 days

  • 50 mg powder in bottle once daily for 14 days

  • DrugPlacebo

    Solution containing no active substance

06

What researchers measure

Primary outcomes

  1. Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score

    Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS video raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

    Time frame: Day 15 and 29, averaged

Secondary outcomes

  1. Clinical Global Impression - Global Improvement of TD (CGI-TD)

    Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).

    Time frame: Day 15 and 29, averaged

07

Results

Posted Aug 10, 2017

Participant flow

This study enrolled patients with a clinical diagnosis of schizophrenia or schizoaffective disorder with moderate or severe symptoms of tardive dyskinesia (TD) from 10 centers in the United States. The last patient completed in February 2012.

Treatment Period 1 (Day 1 to 14)
Participant flow — Treatment Period 1 (Day 1 to 14)
MilestonePlacebo, Then Valbenazine 12.5 mgValbenazine 12.5 mg, Then PlaceboPlacebo, Then Valbenazine 50 mgValbenazine 50 mg, Then Placebo
Started981010
Completed9799
Not completed0111
Withdrew: Protocol violation0100
Withdrew: Withdrawal by subject0010
Withdrew: Adverse event0001
Treatment Period 2 (Day 15 to 28)
Participant flow — Treatment Period 2 (Day 15 to 28)
MilestonePlacebo, Then Valbenazine 12.5 mgValbenazine 12.5 mg, Then PlaceboPlacebo, Then Valbenazine 50 mgValbenazine 50 mg, Then Placebo
Started9799
Completed9778
Not completed0021
Withdrew: Withdrawal by subject0001
Withdrew: Lost to follow-up0010
Withdrew: Physician decision0010
Follow-up Period (Day 29 to 35)
Participant flow — Follow-up Period (Day 29 to 35)
MilestonePlacebo, Then Valbenazine 12.5 mgValbenazine 12.5 mg, Then PlaceboPlacebo, Then Valbenazine 50 mgValbenazine 50 mg, Then Placebo
Started9778
Completed9768
Not completed0010
Withdrew: Withdrawal by subject0010

Outcome measures

PrimaryAbnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score

Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS video raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

Time frame:
Day 15 and 29, averaged
Reported as:
Least squares mean · units on a scale
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score
units on a scalePlaceboValbenazine 12.5 mgValbenazine 50 mg
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score9.9 ± 0.79.1 ± 1.28.8 ± 1.2
Statistical analysis
  • Placebo vs Valbenazine 12.5 mg · ANOVA · p = 0.5880 · Mean difference (final values): -0.7 · 95% CI -3.3 to 1.9
  • Placebo vs Valbenazine 50 mg · ANOVA · p = 0.4184 · Mean difference (final values): -1.1 · 95% CI -3.8 to 1.6
SecondaryClinical Global Impression - Global Improvement of TD (CGI-TD)

Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).

Time frame:
Day 15 and 29, averaged
Reported as:
Mean · units on a scale
Clinical Global Impression - Global Improvement of TD (CGI-TD)
units on a scaleValbenazine 12.5mg PlaceboValbenazine 12.5mgValbenazine 50mg PlaceboValbenazine 50mg
Clinical Global Impression - Global Improvement of TD (CGI-TD)2.2 ± 0.22.2 ± 0.23.2 ± 0.32.6 ± 0.3
Post-hocAbnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score for Combined NBI-98854 Dose Groups (Excluding 1 Site)

Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS video raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

Time frame:
Day 15 and 29, averaged
Reported as:
Least squares mean · units on a scale
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score for Combined NBI-98854 Dose Groups (Excluding 1 Site)
units on a scalePlaceboValbenazine 12.5 mgValbenazine 50 mg
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score for Combined NBI-98854 Dose Groups (Excluding 1 Site)10.3 ± 0.99.9 ± 1.16.1 ± 1.2
Statistical analysis
  • Placebo vs Valbenazine 12.5 mg · ANOVA · p = 0.6761 · Mean difference (final values): -0.4 · 95% CI -2.4 to 1.6
  • Placebo vs Valbenazine 50 mg · ANOVA · p = 0.0015 · Mean difference (final values): -4.2 · 95% CI -6.6 to -1.8

Adverse events

Collected over up to 35 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/35 (0%)0/35 (0%)4/35 (11.4%)
NBI-98854 12.5 mg0/17 (0%)1/17 (5.9%)4/17 (23.5%)
NBI-98854 50 mg0/19 (0%)0/19 (0%)6/19 (31.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboNBI-98854 12.5 mgNBI-98854 50 mg
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/351/170/19
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPlaceboNBI-98854 12.5 mgNBI-98854 50 mg
DiarrhoeaGastrointestinal disorders2/351/170/19
VomitingGastrointestinal disorders0/351/170/19
FuruncleInfections and infestations0/351/171/19
Urine analysis abnormalInvestigations0/351/170/19
Back painMusculoskeletal and connective tissue disorders2/351/170/19
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders0/351/170/19
HeadacheNervous system disorders2/351/170/19
ParaesthesiaNervous system disorders0/351/170/19
FatigueGeneral disorders2/350/170/19
Vision blurredEye disorders0/350/171/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Subjects
Mean51.1 (29 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female15
Male22
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Subjects
Black12
Caucasian15
Hispanic10
Body Mass Index
Body Mass Index(kg/m^2)All Subjects
Mean29.9 (18.1 to 42.0)
Age of Schizophrenia/Schizoaffective Disorder Diagnosis
Age of Schizophrenia/Schizoaffective Disorder Diagnosis(years)All Subjects
Mean25.8 (8 to 54)
Age at TD Diagnosis
Age at TD Diagnosis(years)All Subjects
Mean41.7 (18 to 63)
08

Study locations

11 sites
  • Woodland International Research Group, Inc
    Little Rock, Arkansas 72211, United States
  • Synergy Clinical Research
    National City, California 91950, United States
  • UCSD Outpatient Psychiatry
    San Diego, California 92103, United States
  • PCSD - Feighner Research
    San Diego, California 92108, United States
  • San Marcus Research Clinic, Inc.
    Miami, Florida 33015, United States
  • Medical Research Marseilles
    Miami, Florida 33155, United States
  • Scientific Clinical Research, Inc.
    North Miami, Florida 33161, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • St. Louis Clinical Trials
    Saint Louis, Missouri 63118, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • CAMC Clinical Trials Center
    Charleston, West Virginia 25304, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 5 years 6 months after primary completion. A results delay was requested in Apr 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2011
First posted
Jul 13, 2011
Start
Aug 2011
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results delay requested
Apr 30, 2013
Results first posted
Aug 10, 2017
Last update
Aug 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01393600
Responsible party
Sponsor
First posted
Jul 13, 2011
Start date
Aug 2011
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Aug 10, 2017
Last update
Aug 10, 2017

Study contacts

Christopher O'Brien, MD
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion